# Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

> **NCT00713518** · PHASE2 · COMPLETED · sponsor: **Quark Pharmaceuticals** · enrollment: 152 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** 0.5 mg ranibizumab
- **DRUG:** 3 mg PF-04523655
- **DRUG:** 1 mg PF-04523655

## Key facts

- **NCT ID:** NCT00713518
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-11
- **Final completion:** 2011-07
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2012-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00713518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00713518, "Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00713518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*